Orexigen Therapeutics Inc

Orexigen Therapeutics — Technical Presentation (July 2009)

22 slides from Orexigen Therapeutics's technical presentation, Jul 20, 2009

  1. Slide 1: Addressing the Growing Gap in Obesity Treatment

    Exhibit 99.2 Addressing the Growing Gap in Obesity Treatment Poised for Regulatory and Commercial Success

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Forward-Looking Statements Orexigen cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "poten

  3. Slide 3: Phase III Program Summary

    Phase III Program Summary Contrave Obesity Research (COR) Phase III Program Summary C ontrave O besity R esearch (COR) July 2009 July 2009

  4. Slide 4: OREXIGEN'

    ts OREXIGEN'

  5. Slide 5: OREXIGEN

    ts OREXIGEN SS

  6. Slide 6: Phase III Program Designed for Regulatory and Commercial Success

    Phase III Program Designed for Regulatory and Commercial Success Contrave Obesity Research Trial Patients Enrolled Common Features Phase III Program Designed for Regulatory and Commercial Success Contrave Obesity Research Trial Patients Enrolled Key Features COR – I NB-301 1,742 Two Doses (Contrave1

  7. Slide 7: Slide 7

  8. Slide 8: Slide 8

  9. Slide 9: Slide 9

  10. Slide 10: OREXIGEN'

    is OREXIGEN'

  11. Slide 11: Slide 11

  12. Slide 12: Slide 12

  13. Slide 13: > > ™ EE vs

    > > ™ EE vs GEN

  14. Slide 14: Slide 14

  15. Slide 15: OREXIGEN’

    > Sm : OREXIGEN’

  16. Slide 16: OREXIGEN’

    > na . OREXIGEN’

  17. Slide 17: an

    an 4 12 2 2 36 44

  18. Slide 18: OREXIGEN’

    > Sm : OREXIGEN’

  19. Slide 19: Contrave Exceeded FDA Efficacy Benchmark Across the Phase III Program

    Contrave Exceeded FDA Efficacy Benchmark Across the Phase III Program Key Conclusions Contrave Exceeded FDA Efficacy Benchmark Across the Phase III Program Placebo-ITT Contrave32 -ITT NB-301 NB-304 NB-303 NB-302 Efficacy benchmark In all of our Phase III trials, Contrave crossed the categorical effi

  20. Slide 20: Patients who Complete One Year of Contrave Therapy Lose Even More Weight

    Patients who Complete One Year of Contrave Therapy Lose Even More Weight 25.0 lbs Key Conclusion Patients who Complete One Year of Contrave Therapy Lose Even More Weight Contrave patients in the Phase III program who completed one year of treatment achieved mean weight loss ranging from 5.9% (diabet

  21. Slide 21: Orexigen Poised for Transformation on Positive Contrave Results

    Orexigen Poised for Transformation on Positive Contrave Results Commercialization Differentiation FDA Guidance NDA Filing in 1H 2010 Launch Planning Underway Partnership for Broader Markets Orexigen Poised for Transformation on Positive Contrave Results Attractive Efficacy and Safety Profile Support

  22. Slide 22: ORE XIGE N

    is ORE XIGE N

Orexigen Therapeutics — Technical Presentation (July 2009) on 6ix